Human neprilysin is capable of degrading amyloid β peptide not only in the monomeric form but also the pathological oligomeric form
被引:194
作者:
Kanemitsu, H
论文数: 0引用数: 0
h-index: 0
机构:
Osaka City Univ, Grad Sch Med, Dept Neurosci, Abeno Ku, Osaka 5458585, JapanOsaka City Univ, Grad Sch Med, Dept Neurosci, Abeno Ku, Osaka 5458585, Japan
Kanemitsu, H
[1
]
Tomiyama, T
论文数: 0引用数: 0
h-index: 0
机构:
Osaka City Univ, Grad Sch Med, Dept Neurosci, Abeno Ku, Osaka 5458585, JapanOsaka City Univ, Grad Sch Med, Dept Neurosci, Abeno Ku, Osaka 5458585, Japan
Tomiyama, T
[1
]
Mori, H
论文数: 0引用数: 0
h-index: 0
机构:
Osaka City Univ, Grad Sch Med, Dept Neurosci, Abeno Ku, Osaka 5458585, JapanOsaka City Univ, Grad Sch Med, Dept Neurosci, Abeno Ku, Osaka 5458585, Japan
Mori, H
[1
]
机构:
[1] Osaka City Univ, Grad Sch Med, Dept Neurosci, Abeno Ku, Osaka 5458585, Japan
Amyloid beta-peptide (Abeta) is widely believed to play a central role in Alzheimer's disease (AD). Coordinate regulation of cerebral Abeta level is important in the pathogenesis of AD since either increased production of Abeta from amyloid precursor protein or decreased degradation causes elevated levels of Abeta, leading to accumulation of cerebral plaque formation or amyloid angiopathy. Here we studied neprilysin, a putative proteolytic enzyme for Abeta, and found that it degraded not only monomeric but also oligomeric forms of Abeta1-40. Moreover, neprilysin was found to be capable of degradation of the oligomeric form of Abeta1-42, a significant Abeta species in early pathogenesis. Neprilysin to decrease cerebral Abeta is suggested to be inevitable factor as a vital therapeutic target. (C) 2003 Elsevier Ireland Ltd. All rights reserved.